What organs can TBM-005 be used for?

TBM-005 is currently advancing toward a first-in-human clinical study in lung transplantation. Additional preclinical programs are ongoing in liver, heart, and kidney preservation and perfusion.

How does TBM-005 work with existing perfusion systems?

TBM-005 is being developed as an ex vivo additive intended for integration into existing organ preservation and perfusion workflows. The development approach is intended to support compatibility with current cold storage, flush, and ex vivo perfusion approaches without requiring any dedicated new perfusion device.

What is ischemia-reperfusion injury in organ transplantation?

Ischemia-reperfusion injury can occur when an organ experiences reduced oxygen delivery followed by restoration of oxygenated perfusion. This process may contribute to cellular stress, inflammation, edema, and reduced organ function. DCD and other high-risk donor organs can be particularly vulnerable to these preservation and reperfusion-related stresses.

What is DCD organ transplantation?

DCD stands for Donation after Circulatory Death. These are organs donated after circulatory function has stopped, rather than following brain death donation (DBD). DCD organs may experience warm ischemia, a period of reduced oxygen delivery that can affect organ quality and transplant suitability.

TBM-005 is an ex vivo additive being developed by Targa Biomedical for use with organ preservation and perfusion solutions and systems. It is being developed to support the preservation and functional assessment of donor organs prior to transplantation, which may include DCD organs.